Is Radiation Safe as a Bridging Strategy to CAR T Therapy in Advanced DLBCL?
Researchers tested radiation therapy as a bridging therapy for patients with relapsed/refractory diffuse large B-cell lymphoma during the interval between T-cell collection and final CAR T administration.
Could Gait Speed Predict Outcomes in Older Patients With Blood Cancers?
The gait speed of an older patient with a hematologic malignancy may be an indicator of that patient’s frailty and could predict for worse clinical outcomes.
Better Data on Transplant in Older Patients With Myeloma Needed
A meta-analysis on existing data on the use of autologous stem cell transplant in older patients with newly diagnosed multiple myeloma confirmed the need for randomized controlled trials.
Late Relapse a Possibility Even in DLBCL Patients Disease Free at 2 Years
Late relapses occurred more commonly among patients with DLBCL with concurrent indolent lymphoma at initial diagnosis and those with GCB subtype.
Carfilzomib-Induced Cardiovascular Events Can Be Predicted in Myeloma Patients
Baseline left ventricular diastolic dysfunction may help predict the incidence of severe carfilzomib-induced cardiovascular adverse events in patients with multiple myeloma.
Benefit of Pembrolizumab/Axitinib Combo in Intermediate/Poor-Risk RCC
The KEYNOTE-426 study evaluated pembrolizumab plus axitinib vs sunitinib in patients with metastatic RCC with intermediate/poor risk disease and those with sarcomatoid features.
Carmena Trial: Should Nephrectomy Be Standard for Metastatic RCC?
In this randomized phase III trial, researchers compared cytoreductive nephrectomy vs sunitinib alone in patients with metastatic renal cell carcinoma.
Did Rituximab Maintenance Add Benefit for DLBCL After R-CHOP?
Maintenance rituximab was tested in patients with diffuse large B-cell lymphoma who achieved complete remission after R-CHOP.
Updated Results Show Ongoing Treatment-Free Remission in CML Trial
Updated results from ENESTop show patients with CML remain in treatment-free remission after stopping nilotinib.
Could Lenalidomide Be a New Standard for High-Risk Smoldering Myeloma?
Results from a second clinical trial examined the use of lenalidomide treatment in patients with high-risk smoldering multiple myeloma, where the standard of care has been observation.
Long-Awaited Results of Isatuximab Combo in R/R Myeloma Presented
Researchers evaluated survival and infusion time with combination isatuximab, pomalidomide, and low-dose dexamethasone vs pomalidomide plus low-dose dexamethasone alone in relapsed or refractory multiple myeloma.
SOLO3 Examines Benefit of Olaparib vs Chemo in Platinum-Sensitive Relapsed Ovarian Cancer
This FDA confirmatory phase III study evaluated olaparib vs treatment of physician’s choice in BRCA-mutated, platinum-sensitive relapsed ovarian cancer.
Evaluating Olaparib for BRCA Wild-Type Platinum-Resistant Ovarian Cancer
Data from a phase II study were presented at ASCO 2019, focusing on responses among women with BRCA wild-type ovarian cancer to olaparib.
Benefit of Single-Agent Carboplatin in Vulnerable, Elderly Patients With Ovarian Cancer
The EWOC-1 trial looked at single-agent carboplatin in vulnerable, elderly patients with stage III/IV epithelial ovarian cancer vs weekly or every 3 weeks carboplatin/paclitaxel.
Subcutaneous vs Intravenous Daratumumab: Which Is Better for R/R Myeloma?
The COLUMBA trial examined the efficacy, number of infusion-related reactions, and administration time for SC vs IV daratumumab in R/R multiple myeloma.
Benefits With Gilteritinib for AML Were Maintained, Regardless of Co-Mutations
The survival benefit observed with gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia in the ADMIRAL trial was maintained regardless of the presence of several common co-mutations.
Combo Therapy More Than Doubled PFS in Platinum-Sensitive Recurrent Ovarian Cancer
The phase II AVANOVA trial examined PFS in advanced ovarian cancer patients who received a PARP inhibitor plus bevacizumab.
Anti-BCMA BiTE Immunotherapy: An Option for R/R Multiple Myeloma?
Data from the first-in-human study of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, were presented at ASCO 2019.
Daratumumab + European Standard Yields Clinical Benefit in Transplant Eligible, Newly Diagnosed Myeloma
New data from the CASSIOPEIA trial evaluated the use of daratumumab in addition to bortezomib/thalidomide/dexamethasone after ASCT in multiple myeloma.
Busulfan Added to Conditioning Regimen Effective for Newly Diagnosed Myeloma
A phase III study tested the combination conditioning regimen of busulfan plus melphalan vs standard melphalan alone for patients with newly diagnosed multiple myeloma undergoing transplantation.
Omitting Blue Dye Prior to Mohs Surgery for Melanoma: Is it Safe?
Researchers tested whether use of blue dye injection during sentinel lymph node biopsy can be safely omitted prior to Mohs surgery for malignant melanoma.
Disparities Noted in African American and Caucasian Patients With Myeloma
Researchers looked at survival disparities between African American and Caucasian patients with multiple myeloma.
Is Time to First Distant Recurrence of Advanced Melanoma Linked to Survival?
Researchers looked at whether time to first distant recurrence of metastatic melanoma was linked to survival outcomes.
ASCO: Can Changes in Diet Reduce Deaths From Breast Cancer?
Researchers looked at whether eating a low-fat diet helped improve survival in breast cancer, in a study presented ahead of the ASCO Annual Meeting.
ASCO: Promising Start to Pediatric MATCH Trial
Approximately 25% of patients with tumor samples submitted to the Pediatric MATCH program have been matched to an investigational therapy at an interim analysis reported ahead of the ASCO Annual Meeting.
ASCO: Assessing Low-Dose Chemo in Older, Frail Patients With Gastroesophageal Cancer
Researchers assessed outcomes with different chemo regimen doses in elderly or frail patients with gastroesophageal cancer, in this study presented ahead of the ASCO Annual Meeting.
Natural Killer Cell Levels Could Influence Immunotherapy Outcomes for Lymphoma
Patients with follicular lymphoma or diffuse large B-cell lymphoma with a low peripheral blood natural killer cell count at baseline had shorter time to progression.
Predicting Early Failure in Follicular Lymphoma With PET/CT Characteristics
Researchers have found several characteristics identified on PET/CT that may help to predict early clinical failure of untreated follicular lymphoma.
Percentage of Patients to Benefit From Immune Checkpoint Inhibitors Still Limited
The percentage of patients with cancer eligible to receive immune checkpoint inhibitors has increased in recent years, but how many patients are actually responding?
Adding the T-Cell Booster Decitabine to Anti–PD-1 Therapy in Hodgkin Lymphoma
Researchers tested the addition of the T cell–boosting decitabine to anti–PD-1 therapy with camrelizumab among patients with relapsed or refractory classic Hodgkin lymphoma.